Skip to main content

Table 1 T2DM patients basal characteristics

From: Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study

  Control
n 214
T2DM
n 100
p value
Age (year) 49 (41–58) 54 (48–61) <0.001
BSA (m2) 1.82 ± 0.21 2.06 ± 0.25 <0.001
BMI (kg/m2) 26.19 ± 5.37 34.32 ± 7.48 <0.001
Female sex (%) 76.9 61.0 <0.01
Creatinine (mg/dl) 0.9 (0.8–1.0) 0.9 (0.8–1.1) 0.34
GFR c–c (ml/min) 86.7 (69.5–107.1) 112.5 (85.8–144.2) <0.001
GFR MRDR (ml/min) 73.3 (65.4–86.6) 74.1 (62.1–88.9) 0.96
Risk factors and CAD history (%)
 Current smoker 11.2 9.0 0.69
 Hypertension 34.2 69.7 <0.001
 Hyperlipidemia 46.9 78.9 <0.001
 Postmenopausal 35.2 44.4 0.11
 CAD family history 60.5 57.0 0.43
Inflammatory markers
 Lpa (mg/dl) 11.0 (7.0–25.0) 13.5 (7–35.7) 0.16
 hsCrP (mg/l) 0.4 (0.2–1.1) 1.0 (0.4–3.8) <0.001
 Homocysteine (µmol/l) 7.0 (6.0–9.0) 8.0 (6.0–10.0) 0.15
Coronary epicardial and microvascular function
 CFR 2.9 (2.5–3.3) 2.8 (2.3–3.5) 0.71
 CRF < 2.5 (%) 27.2 % 35.0 % 0.18
 CBF%Ach 63.3 (9.4–131.4) 25.2 (−20.5 to 68.8) <0.001
 CBFAch < 50 % (%) 41.3 % 62.0 % <0.001
 CLD%Ach –7.7 (−18.7 to 0.0) −11.4 (−27.1 to 3.1) <0.05
 CLDAch < 20 % (%) 21.6 % 32.0 % 0.051
 CBFbasal 50.2 (34.0–73.5) 52.6 (37.8–72.6) 0.42
 LVEDP (mmHG) 13.5 (11.0–23.0) 17.0 (13.0–26.0) <0.001
Medication (%)
 BBlockers 24.4 41.0 <0.01
 CC blockers 36.0 32.0 0.52
 Nitrates 32.2 45.0 <0.05
 ASA 50.7 64.0 <0.05
 ACE/ARB inhibitor 17.8 34.0 <0.01
 Lipid lowering 33.8 59.0 <0.001
  1. BMI body mass index, BSA body surface area, GFR cc Cockroft–Gault glomerular filtrate rate, CAD coronary artery disease, Lpa lipoprotein A, hsCrP high sensitive C reactive protein, CFR coronary flow reserve, CMD coronary microvascular dysfunction, CFR < 2.5 independent CMD, CBF%Ach percentage of increase in CBF after intracoronary acetylcholine infusion, CBFAch < 50 % dependent CMD, CLD%Ach percentage of increase in coronary lumen diameter after intracoronary acetylcholine infusion, CLDAch < 20 % epicardial endothelial dysfunction, LVEDP left ventricular end-diastolic pressure, CC blockers calcium channel blocker, ASA acetylsalicylic acid, ACE/ARB inhibitor angiotensin-converting enzyme/angiotensin inhibitor.